Literature DB >> 9519983

Topical tacrolimus for pyoderma gangrenosum.

H C Schuppe, B Homey, T Assmann, R Martens, T Ruzicka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9519983     DOI： 10.1016/S0140-6736(05)78962-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

2.  [Multimodal treatment of pyoderma gangrenosum].

Authors:  N-P Hoff; B Homey; D Bruch-Gerharz; H Stege
Journal:  Hautarzt       Date:  2008-04       Impact factor: 0.751

3.  Pyoderma gangrenosum.

Authors:  Norman-Philipp Hoff; Edwin Bölke; Christiane Matuschek; Matthias Peiper; Norbert J Neumann; Peter Arne Gerber
Journal:  Wien Klin Wochenschr       Date:  2010-02       Impact factor: 1.704

4.  Pyoderma gangrenosum associated with chronic polyarthritis.

Authors:  Norman-Philipp Hoff; Peter Arne Gerber
Journal:  CMAJ       Date:  2011-08-22       Impact factor: 8.262

Review 5.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

6.  Pyoderma gangrenosum: From historical perspectives to emerging investigations.

Authors:  Misty M Hobbs; Alex G Ortega-Loayza
Journal:  Int Wound J       Date:  2020-05-06       Impact factor: 3.315

Review 7.  Effective Strategies for the Management of Pyoderma Gangrenosum.

Authors:  Heidi Goodarzi; Raja K Sivamani; Miki Shirakawa Garcia; Lisa N Wehrli; Hilary Craven; Yoko Ono; Emanual Maverakis
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-10       Impact factor: 4.730

Review 8.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.